Supernus Pharmaceuticals, INC Schedule 13G passive stakes

Filings indicate a shift in beneficial ownership of Supernus Pharmaceuticals, Inc. common stock by Millennium Management LLC and affiliated entities.

Vanguard Capital Management has reported beneficial ownership of 5.03% of Supernus Pharmaceuticals Inc.'s common stock as of March 31, 2026.

Vanguard Portfolio Management has reported beneficial ownership of 5.66% of Supernus Pharmaceuticals Inc.'s common stock as of March 31, 2026.

The Vanguard Group reported 0% beneficial ownership in Supernus Pharmaceuticals Inc. following an internal realignment of its reporting structure.

Millennium Management LLC and affiliates have reported a 5.3% beneficial ownership stake in Supernus Pharmaceuticals, Inc. common stock.

Dimensional Fund Advisors LP has reported a 4.7% beneficial ownership stake in Supernus Pharmaceuticals Inc. common stock as of December 31, 2025.

Armistice Capital, LLC and Steven Boyd have reported a 5.06% beneficial ownership stake in Supernus Pharmaceuticals, Inc., totaling 2,836,000 shares.

Armistice Capital, LLC and Steven Boyd reported beneficial ownership of 8.58% of Supernus Pharmaceuticals, Inc. common stock, totaling 4,812,000 shares.

Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, confirming their beneficial ownership of 9.28% of Supernus Pharmaceuticals, Inc.'s common stock as of March 31, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, revealing a 14.7% beneficial ownership stake in Supernus Pharmaceuticals, Inc. as of March 31, 2025.

Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, disclosing a beneficial ownership of 8.76% in Supernus Pharmaceuticals, Inc. as of December 31, 2024.